Raymond James analyst Sean McCutcheon initiated coverage of Janux Therapeutics (JANX) with an Outperform rating and $65 price target Janux is clinical-stage company focused on developing masked T-cell engagers for several cancer types, the analyst tells investors in a research note. The firm sees good results to date for JANX007, saying the data offer “strong proof-of-concept” for the masking technology employed by Janux.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics Holds 2025 Annual Stockholders Meeting
- Promising Developments and Market Potential of Janux Therapeutics Inc.: A Focus on JANX007 and JANX008 Trials
- Janux appoints Janeen Doyle chief corporate, business development officer
- Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion